Details from lymph node evaluations
| Characteristics | N | Nodal metastasis, n | % | P value |
| Patients who underwent node sampling | 56 | 10 | 17.9 | |
| Gross appearance | <0.001 | |||
| No LAD or EUD | 29 | 1 | 3.4 | |
| LAD without EUD | 8 | 4 | 50.0 | |
| EUD without LAD | 11 | 1 | 9.1 | |
| EUD and LAD | 8 | 4 | 50.0 | |
| Gross appearance | 0.005 | |||
| No LAD or EUD | 29 | 1 | 3.4 | |
| LAD or EUD or both | 27 | 9 | 33.3 | |
| Gross appearance | <0.001 | |||
| No LAD | 40 | 2 | 5.0 | |
| LAD | 16 | 8 | 50.0 | |
| LVSI | 0.57 | |||
| (−) LVSI | 7 | 0 | 0 | |
| (+) LVSI | 42 | 7 | 16.7 | |
| Unavailable | 7 | 3 | 42.9 | |
| Uterine tumor size | 0.68 | |||
| ≤5 cm | 21 | 3 | 14.3 | |
| >5 cm | 17 | 4 | 23.5 | |
| Unavailable | 18 | 3 | 16.7 |
EUD, extra-uterine disease; LAD, lymphadenopathy ; LVSI, lymphovascular space invasion.